News
Seae Ventures launches US$107m fund to address equity gaps in healthcare
The fund seeks to make investment landscape more equitable and address inequities in healthcare
The Boston-based venture capital firm, Seae Ventures, has announced its inaugural fund of US$107m.
Seae is the largest fund dedicated to advancing equity by investing in women and Black, Indigenous and People of Colour (BIPOC) entrepreneurs, focused on developing technologies that address financial wellness, mental health, women’s health and personalised medicine that benefit traditionally underserved and vulnerable populations.
“It is a well-known fact that women and BIPOC entrepreneurs have not had equal access to capital,” says Jason Robart, Seae Ventures, co-founder and managing partner. “Closing gender and racial equity gaps starts with investing in historically overlooked entrepreneurs.
“We are confident our efforts will motivate other venture firms to recognise this unseen value and amplify our portfolio’s collective mission through investment and support.”
Co-founded in 2019 by Tuoyo Louis, Jason Robart and Pete Sally, Seae is driven by a mission born from their personal experiences and frustration with the widening health disparities across the country.
The firm has garnered support from a broad coalition of more than 30 investors who are dedicated to increasing the prevalence of venture firms with diverse leadership, including the American Hospital Association, Blue Shield of California, Blue Cross Blue Shield of Minnesota, Cambridge Associates, Eli Lilly and Company, Goldman Sachs and Health Care Service Corporation.
Seae aims to change the overall U.S. healthcare system, having already funded 17 start-ups addressing the country’s most pressing healthcare disparities, including:
- Health in Her HUE, a platform designed to help Black women and women of colour easily access culturally sensitive healthcare providers, health content, and community
- Hurdle, an innovative digital mental health platform company aiming to remove barriers to mental health care for People of Colour
- MD Ally, a company that triages 911 calls and reroutes non-emergency calls to telehealth medical services
- Moving Analytics, a telehealth company providing virtual cardiac rehab solutions
- Tia, a company building the “modern medical home for women” across virtual and in-person care
While the initial fund is closed, Seae will continue to build their firm while enhancing equitable access to capital for diverse entrepreneurs building growth stage companies in future funds.
“Seae Ventures’ mission to drive capital toward diverse founders is not just reflective of our shared goals and values, it is also aligned with our investment thesis, which is to affect supply and demand dynamics,” Jasmine Richards, managing director at Cambridge Associates, has explained.
For more info, visit seaeventures.com.
Diagnosis
Lung cancer drug shows breast cancer potential
Ovarian cancer cells quickly activate survival responses after PARP inhibitor treatment, and a lung cancer drug could help block this, research suggests.
PARP inhibitors are a common treatment for ovarian cancer, particularly in tumours with faulty DNA repair. They stop cancer cells fixing DNA damage, which leads to cell death, but many tumours later stop responding.
Researchers identified a way cancer cells may survive PARP inhibitor treatment from the outset, pointing to a potential way to block that response. A Mayo Clinic team found ovarian cancer cells rapidly switch on a pro-survival programme after exposure to PARP inhibitors. A key driver is FRA1, a transcription factor (a protein that turns genes on and off) that helps cancer cells adapt and avoid death.
The team then tested whether brigatinib, a drug approved for certain lung cancers, could block this response and boost the effect of PARP inhibitors. Brigatinib was chosen because it inhibits multiple signalling pathways involved in cancer cell survival.
In laboratory studies, combining brigatinib with a PARP inhibitor was more effective than either treatment alone. Notably, the effect was seen in cancer cells but not normal cells, suggesting a more targeted approach.
Brigatinib also appeared to act in an unexpected way. Rather than working through the usual DNA repair routes, it shut down two signalling molecules, FAK and EPHA2, that aggressive ovarian cancer cells rely on. FAK and EPHA2 are proteins that relay survival signals inside cells. Blocking both at once weakened the cells’ ability to adapt and resist treatment, making them more vulnerable to PARP inhibitors.
Tumours with higher levels of FAK and EPHA2 responded better to the drug combination. Other data link high levels of these molecules to more aggressive disease, pointing to potential benefit in harder-to-treat cases.
Arun Kanakkanthara, an oncology investigator at Mayo Clinic and a senior author of the study, said: “This work shows that drug resistance does not always emerge slowly over time; cancer cells can activate survival programmes very early after treatment begins.”
John Weroha, a medical oncologist at Mayo Clinic and a senior author of the study, said: “From a clinical perspective, resistance remains one of the biggest challenges in treating ovarian cancer. By combining mechanistic insights from Dr Kanakkanthara’s laboratory with my clinical experience, this preclinical work supports the strategy of targeting resistance early, before it has a chance to take hold. This strategy could improve patient outcomes.”
Insight
Higher nighttime temps linked to increased risk of autism diagnosis in children – study
Entrepreneur
Kindbody unveils next-gen fertility platform
-
Insight4 weeks agoDesigner perfumes recalled over banned chemical posing fertility risk
-
Insight2 weeks agoParents sue IVF clinic after delivering someone else’s baby
-
Insight3 weeks agoWomen’s health could unlock US$100bn by 2030
-
Insight4 weeks agoChina’s birth rate hits record low despite government fertility efforts
-
Wellness3 weeks agoHRT linked to greater weight loss on tirzepatide
-
Entrepreneur6 days agoUS startup builds wearable hormone tracker
-
Menopause2 weeks agoFlo Health and Mayo Clinic publish global perimenopause awareness study
-
News4 weeks agoVerdane invest in Clue to accelerate the future of women’s health







3 Comments